Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
Hypoxia-inducible factor-1 alpha is involved in RIP-induced necroptosis caused by in vitro and in vivo ischemic brain injury
CCR-13-1777
Solubility: DMSO: 5 mg/mL(13
LY2784544 was used at 5-10 µM final concentration in vitro and in cellular assays
24-48 hours) inhibits LnCAP and MCF7 cells viability in a dose-dependent manner
Tofogliflozin hydrate Catalog No.:M10025-2 Hypoxia-inducible factor-1 alpha is involvedTofogliflozin, also known as CSG 452, is a potent and high selective SGLT2 inhibitor under development the treatment of diabetes mellitus. Tofogliflozin improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus. Tofogliflozin dose dependently suppressed glucose entry into tubular cells. High glucose exposure (30 mM) for 4 and 24 h significantly increased oxidative stress generation in tubular cells, which were